Mantle Cell Lymphoma
Conditions
Keywords
Mantle Cell Lymphoma, BTK inhibitor, Rocbrutinib
Brief summary
Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits both covalent (irreversible) and non-covalent (reversible) binding. This unique dual mechanism of action has shown promising efficacy and a favorable safety profile across various B-cell NHL subtypes in prior Phase 1 and 2 studies. This is a Phase 3, randomized, open-label study comparing Rocbrutinib versus investigator's choice of BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or orelabrutinib) in patients with MCL who have received at least one prior line of therapy and are naïve to BTK inhibitor treatment (except for intolerance).
Interventions
DRUGRocbrutinib
Rocbrutinib at 150 mg once daily orally until disease progression or unacceptable toxicity
DRUGIbrutinib
Ibrutinib, 560 mg once daily orally and continuously
DRUGAcalabrutinib
Acalabrutinib, 100 mg twice daily orally and continuously
DRUGZanubrutinib
Zanubrutinib, 160 mg twice daily orally and continuously
DRUGOrelabrutinib
Orelabrutinib, 150 mg once daily orally and continuously
Sponsors
Guangzhou Lupeng Pharmaceutical Company LTD.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosed with MCL, who have received at least one prior systemic regimen(s), and have experienced disease progression on the most recent line of therapy. * Have at least one measurable lesion according to the Lugano Response Criteria 2014. * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2. * Life expectancy ≥ 12 weeks. * Adequate coagulation function, liver and kidney function, bone marrow hematopoietic function, etc. * Toxicities or complications from prior anti-tumor therapy have recovered to Grade ≤1 according to NCI CTCAE v5.0. * All male subjects and female subjects of childbearing potential must strictly use medically approved contraception throughout the entire study period. All male subjects must also avoid sperm donation during the above period. For women of childbearing potential, the result of serum pregnancy test must be obtained. Women must be non-lactating. * Subject voluntarily enrolls and signs the informed consent form, and agrees to comply with the study treatment plan and visit schedule.
Exclusion criteria
* Hypersensitivity to Rocbrutinib or any study drug in the control group. * Prior treatment with any BTK-targeted therapy (except for intolerance). * Central nervous system (CNS) involvement by lymphoma. * History of other malignancy (except MCL) within the past 2 years, excluding radically cured skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, localized squamous cell carcinoma, etc. * History of major cardiovascular events within 6 months prior to randomization. * Presence of any severe and/or uncontrolled systemic disease that, in the investigator's judgment, or have poor cardiac function. * Uncontrolled active bacterial, fungal, or viral systemic infection, or active tuberculosis infection. * Any medical condition that could interfere with the absorption, distribution, metabolism, or excretion (ADME) of the investigational drug or the evaluation of study outcomes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) assessed by IRC | approximately 30 months |
Secondary
| Measure | Time frame |
|---|---|
| PFS assessed by INV | approximately 30 months |
| Overall Response Rate (ORR) assessed by IRC and INV, respectively | Up to approximately 24 months |
| Duration of Response (DOR) assessed by IRC and INV, respectively | approximately 30 months |
| Overall Survival | approximately 40 months |
| Number of participants with treatment-emergent adverse event as assessed by CTCAE v5.0 | Up to approximately 40 months |
| Number of participants with treatment-related adverse event as assessed by CTCAE v5.0 | Up to approximately 40 months |
Countries
China
Contacts
CONTACTYuqin Song
Outcome results
None listed